Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 23 January 2017 | By Zachary Brennan
The European Commission on Monday unveiled a new question and answer document for those looking to better understand biosimilars.
Similar to the Focus explainer on biosimilars, the 9-page EC explainer, available in seven languages, offers a quick 10,000-foot view of the biosimilars landscape, answering questions that patients might have on what a biologic is, what a biosimilar is, how biosimilars compare to generics, what types of studies biosimilars must undergo prior to approval and how to define extrapolation.
In addition to offering links to additional sources of information for patients, the explainer also provides a quick rundown on what to do if a biosimilar leads to an adverse event, as well as a list of currently available biosimilars in the EU.
Meanwhile, for the third year in a row, the commission will also organize a multi-stakeholder workshop on biosimilar medicines on 5 May 2017. This year, the focus will be on developing a Q&A for healthcare professionals, the groups said in a statement.
Q&A for patients - Biosimilar medicines explained
Tags: biosimilars, biosimilar workshop
Regulatory Focus newsletters
All the biggest regulatory news and happenings.